让银屑病患者参与局部治疗的依从性与结局:2021年第30届EADV大会研讨会「根据患者需求与期望定制局部银屑病治疗」摘要
本文基于2021年第30届EADV大会卫星研讨会的报告,讨论影响局部治疗依从性与结局的因素,重点关注患者视角。银屑病可导致抑郁、焦虑等心理社会影响,自杀风险高于背景人群;依从性可能是局部治疗成功的最大障碍,医患共同决策可改善用药依从性与治疗成功。基于PAD技术的CAL/BDP新型复方乳膏具有高化妆品接受度和总体治疗满意度。
要点
- 银屑病可致抑郁、焦虑,自杀风险高于背景人群。
- 依从性可能是局部治疗成功的最大障碍。
- 医患共同决策可改善用药依从性与治疗成功。
核心结论
- 依从性可能是局部治疗成功的最大障碍,改善疾病管理多个方面可提高依从性并带来临床获益。
- 患者参与银屑病管理可预防心理社会共病,且需以多学科方式治疗。
研究设计与样本
- 本文基于2021年第30届欧洲皮肤病与性病学会(EADV)大会卫星研讨会「根据患者需求与期望定制局部银屑病治疗」的作者报告。
主要发现
- 银屑病不只是一种皮肤状况,可造成抑郁和焦虑等负面心理社会影响。
- 银屑病患者自杀风险高于背景人群。
- 不依从的治疗相关因素包括患者不满意、副作用、治疗方案或药物载体。
- CAL/BDP乳膏是一种基于Poly-Aphron Dispersion(PAD)技术的CAL/BDP固定剂量复方新剂型,用于轻至中度斑块状银屑病(包括头皮银屑病),具有高化妆品接受度和总体治疗满意度。
关键数值与推荐
- 向患者提供全面治疗信息有助于建立现实的目标和期望。
- 已显示医患共同决策可改善用药依从性和治疗成功。
- 按患者对治疗载体的偏好开具治疗并改善医患沟通,可能是最大化依从性的关键因素。
临床怎么用
- 患者需参与治疗策略的选择,因银屑病患者对局部治疗的使用有多种偏好。
- 按患者对治疗载体的偏好开具治疗并改善医患沟通,可能是最大化依从性的关键因素。
- 医患共同决策已显示可改善用药依从性和治疗成功。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This article is based on a presentation given by authors at the Satellite Symposium titled 'Tailoring topical psoriasis treatments to patients' needs and expectations' held during the 30th European Academy of Dermatology and Venereology Congress. During this session, the factors affecting adherence and outcomes to topical treatments were presented, with a particular focus on the patients' point of view. Psoriasis is not just a skin condition. Psoriasis can cause negative psychosocial effects, such as depression and anxiety. The risk of suicidality in patients with psoriasis is higher than in the background population. Psychosocial comorbidities can be prevented by patient involvement in psoriasis management and need to be treated in a multidisciplinary manner. Adherence may be the largest barrier to treatment success with topical therapies. Improvement in several areas of disease management may lead to benefits in treatment adherence and hence clinical benefit. There are several treatment-related factors for non-adherence, such as patient dissatisfaction, side effects, treatment regimen or the drug vehicle. Delivering comprehensive treatment information to the patient will help develop realistic objectives and expectations. Patients need to be involved in the selection of treatment strategies, as psoriasis patients have various preferences for their use of topical treatments. A shared decision-making with the patient has been shown to improve medication adherence and treatment success. Prescribing therapy in line with a patient preference for treatment vehicle and improving the communication between healthcare professionals and patients may be key factors to maximize adherence. The calcipotriol (CAL) and betamethasone dipropionate (BDP) cream, a novel formulation of the CAL/BDP fixed-dose combination based on Poly-Aphron Dispersion (PAD) Technology, is a topical treatment of mild-to-moderate plaque psoriasis, including scalp psoriasis, that has high cosmetic acceptance and overall treatment satisfaction.
引用
- Bewley A, van de Kerkhof P. Engaging psoriasis patients in adherence and outcomes to topical treatments: A summary from the Symposium 'Tailoring topical psoriasis treatments to patients' needs and expectations' of the 30th EADV Congress 2021. J Eur Acad Dermatol Venereol. 2023. PMID: 36546463. doi:10.1111/jdv.18751
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。